过去一年中添加的文章，按日期排序
Exploring the safety of combination therapy with SGLT-2 and DPP-4 inhibitors in type 2 Diabetes mellitus
PS Shemeer, FA Khan, H Ashraf - … & Drug Safety, 2024 - journalofsopi.com
63 天前 - … Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the
clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369 11. Mascolo, A., Di …
clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369 11. Mascolo, A., Di …
[PDF][PDF] Retrospective Observational Study on Assessing Sitagliptin and Dapagliflozin as a Fixed-Dose Combination in the Indian Population With Type 2 Diabetes …
M Chawla, D Panneerselvam, A Gundgurthy, S Sud… - Cureus, 2024 - cureus.com
73 天前 - … 2 (SGLT2) and dipeptidyl peptidase 4 (DPP-4) inhibitors in T2DM. This investigation
… (FDC) of sitagliptin and dapagliflozin, offering insights into its safety and efficacy for the …
… (FDC) of sitagliptin and dapagliflozin, offering insights into its safety and efficacy for the …
Developing 2-Aminothiophene Derivatives as Positive Allosteric Modulators of Glucagon-Like Peptide 1 Receptor
Z Li, P Do, Z Li, F Malik - 2024 - ASPET
89 天前 - … with sitagliptin, an inhibitor of the GLP-1 degrading enzyme dipeptidyl peptidase
IV, … approximately 75% after 60 minutes, confirming its effectiveness as a PAM of GLP-1R. …
IV, … approximately 75% after 60 minutes, confirming its effectiveness as a PAM of GLP-1R. …
Anticancer and Antioxidant Effects of Sitagliptin and Linagliptin against Lung Cancer Cell Lines (an In vitro Study).
AM Al Khafaji, AF Bairam - Tropical Journal of Natural …, 2024 - search.ebscohost.com
94 天前 - … The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and
ameliorates glomerular lesions in a rat model of type 1 diabetes. Life Sci. 2019;234:116738. …
ameliorates glomerular lesions in a rat model of type 1 diabetes. Life Sci. 2019;234:116738. …
[PDF][PDF] Synergistic Antitumor and Apoptotic Activity of Sitagliptin or Linagliptin Plus Cisplatin Against A549 Lung Cancer Cells (An Invitro Study).
AM Al Khafaji, AF Bairam - Journal of Contemporary Medical Sciences, 2024 - iasj.net
94 天前 - … and improved safety profiles for normal cells. Dipeptidyl peptidase-4 inhibitors
have … Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic …
have … Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic …
Low-Dose Sulfonylurea Plus DPP4 Inhibitor Lower Blood Glucose and Enhance Beta-Cell Function Without Hypoglycemia
RLM Cordiner, K Bedair, A Mari… - The Journal of Clinical …, 2024 - academic.oup.com
192 天前 - … need to provide cost-effective diabetes care, including how we modernize our
use of our cheaper generic therapies such as SUs and dipeptidyl peptidase 4 inhibitors (DPP4is). …
use of our cheaper generic therapies such as SUs and dipeptidyl peptidase 4 inhibitors (DPP4is). …
Prusogliptin (DBPR108) monotherapy in treatment‐naïve patients with type 2 diabetes: A randomized, double‐blind, active and placebo‐controlled, phase 3 study
W Wang, X Guo, C Zhang, T Ning, G Ma… - Diabetes, Obesity …, 2024 - Wiley Online Library
201 天前 - … This study aimed to assess the efficacy and safety of prusogliptin (DBPR108), a
novel and highly selective dipeptidyl peptidase-4 inhibitor, in individuals with type 2 diabetes …
novel and highly selective dipeptidyl peptidase-4 inhibitor, in individuals with type 2 diabetes …
[HTML][HTML] Nec 1s Inhibitor
M Lee, MK Rhee - nec-1sinhibitor.com
207 天前 - … Sitagliptin, a dipeptidyl peptidase 4 inhibitor, was the first in its class to receive
approval from the US FDA in 2006 for the treatment of Type 2 diabetes mellitus. It has been …
approval from the US FDA in 2006 for the treatment of Type 2 diabetes mellitus. It has been …
Sitagliptin for Prevention of aGVHD in Patients Received Alternative Donor Transplantations: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
M Qiao, X Yang, X Bao, J Zhou, H Zhu, Y Zhang, T You… - Blood, 2023 - Elsevier
249 天前 - … Sitagliptin is a selective inhibitor of dipeptidyl peptidase 4 (DPP-4; also known as
CD26)… This trial aims to evaluate the safety and ef cacy of sitagliptin plus a calcineurin inhibitor…
CD26)… This trial aims to evaluate the safety and ef cacy of sitagliptin plus a calcineurin inhibitor…
Abstract# 1555775: In Vitro Study of Antimicrobial Properties of Some Dipeptidyl Peptidase IV Inhibitors
A Unis, G Menezes - Endocrine Practice, 2023 - endocrinepractice.org
260 天前 - … Dipeptidyl peptidase-4 (DPP-4) inhibitors are a … safety and efficacy. Accordingly,
the aim of the current study is to investigate the antimicrobial potential of some DPP-4 inhibitors …
the aim of the current study is to investigate the antimicrobial potential of some DPP-4 inhibitors …